Entresto Falls in PARADISE-MI; Old Biomarkers, New Tricks; DeepFake ECGs
Forbes) Heart attack survivors saw no reduction in cardiovascular death and heart failure using sacubitril/valsartan (Entresto) compared with ramipril, Novartis said. More details on the PARADISE-MI trial are to be announced at the American College of Cardiology meeting later this month. ( FiercePharma) Switching to high-sensitivity cardiac troponin testing in the emergency department was associated with more findings of myocardial injury and MI, but no overall increase in resource use (except angiography), a health system found in its Wisconsin hospitals. ( Journal of the American College of...
Source: medpagetoday.com